Company
Oxford Cannabinoid Technologies Holdings PLC
LON:OCTP
Oxford Cannabinoid Technologies Holdings PLC is a well-established, innovative and growing pharmaceutical company developing a portfolio of next generation prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the multi-billion dollar pain market.
54 stories · page 2 of 3
Oxford Cannabinoid Technologies names Paul Smalley as new finance director
Smalley has more than 25 years' UK and international financial experience including strategic management capabilities gained across a wide range of market sectors
Oxford Cannabinoid Technologies errs of the side of 'prudence' with budget review
The group is developing prescription cannabinoid medicines targeting the multi-billion dollar pain market
Oxford Cannabinoid holds first Scientific Advisory Board meeting
The SAB provided advice and guidance on the design of the company's upcoming Phase 1 clinical trials
Oxford Cannabinoid Technologies: Is the market underestimating its true potential?
“In our view, this is an interesting opportunity," said Dr John Savin, healthcare analyst at Proactive Research
Oxford Cannabinoid Technologies says two lead drugs will be in the clinic by Q1 2023
The company’s aim is to develop non-addictive, cannabinoid-based prescription pain medicines for “people who the opioid crisis has left behind”
Oxford Cannabinoid appoints Simbec-Orion to run first clinical trial on lead compound
Simbec-Orion has 45 years of specialist expertise in clinical pharmacology and lab expertise
Oxford Cannabinoid Technologies says lead assets are on track
The biopharmaceutical company is developing cannabinoid treatments to combat pain
Oxford Cannabinoid forms scientific advisory board
The initial focus will be on the design of the pharmaceutical company’s upcoming phase 1 clinical trials
Oxford Cannabinoid Technologies to focus neuropathic pain strategy on small fibre neuropathies
The company said there this a large unmet medical need in chemotherapy-induced peripheral neuropathy
Oxford Cannabinoid Technologies' preclinical study of lead asset returns encouraging pre-clinical results
OCT461201 was shown to reduce pain associated with chemotherapy-induced peripheral neuropathy
Oxford Cannabinoid makes progress on all drug development programmes
Research costs of early £1m went towards its four cannabinoid prescription drugs in the first half of its 2021 financial year
Oxford Cannabinoid adds Imperial Brands representative to board
The company also confirmed that Julie Pomeroy will take over as chair next month
Oxford Cannabinoid Technologies says financial results for half year in line with expectations as it updates on trial timelines
Investors were also provided with updated guidance on its two planned clinical programmes
Oxford Cannabinoid starts trading on OTCQB Market in US
“It will increase liquidity and significantly enhance the ability of US-based investors to access and trade OCTP shares.”
Oxford Cannabinoid Technologies brings in a specialist R&D firm to help it unlock the potential of Canopy Growth library
The end goal of the collaboration with the Canadian group Dalriada is to select two drug candidates ready for pre-clinical development by the end of next year